Spotlight
Clinical
Conferences
CME/CE
Clinical Trials in Adjuvant IO Therapy for RCC
Tian Zhang, MD, explains whether recent data from ESMO 2022 has changed their approach to adjuvant immune therapy in advanced RCC.
EP: 1.CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes
EP: 2.CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings
EP: 3.Observing Patients with Advanced Renal Cell Carcinoma Before Systemic Therapy
EP: 4.Impact of the CLEAR Trial Data Updates in Clinical Practice
EP: 5.Approaches to the Frontline Treatment of Advanced Kidney Cancer
EP: 6.Switching a Patient with Advanced RCC Between IO + TKI and IO + IO Combination Regimens
EP: 7.Approaches to Dosing TKIs in Patients with Advanced RCC
EP: 8.COSMIC-313 Trial of Cabozantinib, Nivolumab and Ipilimumab in Frontline Advanced RCC
EP: 9.Phase III Trial of Lenvatinib, Pembrolizumab, and Belzutifan or Quavonlimab in Frontline Advanced RCC
Now Viewing
EP: 10.Clinical Trials in Adjuvant IO Therapy for RCC
EP: 11.Disease Progression After Adjuvant Pembrolizumab Therapy for RCC
EP: 12.Frontline Therapy for Non-Clear Cell RCC
EP: 13.Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed
Related Videos
Related Content
